Authors:
Julia M. Berger (1)*, Pia Gattinger, PhD (2)*, Maximilian J. Mair, MD
(1), Anna S. Berghoff, MD, PhD (1), Rudolf Valenta, MD (2), Matthias
Preusser, MD (1)
Division of Oncology and Christian Doppler Laboratory for Personalized
Immunotherapy, Department of Medicine I, Medical University of Vienna,
Vienna, Austria
Division of Immunopathology, Department of Pathophysiology and Allergy
Research, Center for Pathophysiology, Infectiology and Immunology,
Medical University of Vienna, Vienna, Austria
*shared first authors
Corresponding Author:
Matthias Preusser, MD, Division of Oncology,
Department of Medicine I, Medical University of Vienna, Waehringer
Guertel 18-20, 1090 Vienna, Austria (matthias.preusser@meduniwien.ac.at)
Word count: 579 (of 600)
Number of figures and tables: 2
Acknowledgements: We thank Hannah Puhr, MD, Dominikus Huber,
MD, Cornelia Englisch, MD, Lynn Gottmann, Martin Korpan, and Markus
Kleinberger for support with sample and data collection. None of these
individuals received additional compensation for their contribution.
Written permission to include these individuals in this section has been
obtained.
Source(s) of support: This study was funded by the Austrian
Federal Ministry for Digital and Economic Affairs; the National
Foundation for Research, Technology and Development; and the Christian
Doppler Research Association. This study was also funded from the
research budget of the Medical University of Vienna. . The funding
organizations had no role/influence in design and conduct of the study;
collection, management, analysis, and interpretation of the data;
preparation, review, or approval of the manuscript; and decision to
submit the manuscript for publication.
Conflict of Interest: Dr Mair reported receiving nonfinancial
support from Pierre Fabre outside the submitted work. Dr Valenta
reported receiving personal fees from Viravaxx AG and Worg
Pharmaceuticals; receiving grants from HVD Biotech, Viravaxx AG, and
Worg Pharmaceuticals outside the submitted work; and holding a patent
for Molecular Interaction Assay (pending) and a patent for SARS-CoV-2
vaccine (pending). Dr Preusser reported receiving personal fees from
Bayer, Bristol Myers Squibb, Novartis, Gerson Lehrman Group, CMC
Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia,
AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck
Sharp & Dohme, Tocagen, Adastra, and Gan & Lee Pharmaceuticals outside
the submitted work. No other disclosures were reported.